Renalytix expands US footprint with three new clinical partnerships

Renalytix has completed clinical integrations of its FDA-approved KidneyIntelX test with three US provider groups — Joseph P. Addabbo Family Health Center (NY), Central Florida Kidney Specialists, and The Kidney Experts PLLC (TN) — and reports initial patient testing is underway with modest starting volumes. Integrations connect the test into providers' electronic health records for one-click ordering, supporting the company's disciplined rollout and expected steady uptake; Renalytix is also collaborating with Tempus AI (since Sept 2025) to target large diabetes/kidney populations and will provide a fuller trading and progress update in February.

Analysis

Market structure: Renalytix (AIM:RENX / OTC:RNLXY) and Tempus (TEM) are the direct beneficiaries — Renalytix gains incremental addressable market via EHR integrations and Tempus accrues value as an adoption conduit for AI-enabled diagnostics. Incumbent downstream service providers (large dialysis operators like DVA/FMS) face long-tail demand risk if early-detection testing meaningfully delays dialysis starts, but that risk is low-medium over 1–3 years given current modest volumes. Pricing power for Renalytix depends on payer coverage; absent broad CMS reimbursement the test will remain volume-constrained and provider-driven, not price-setting.

Risk assessment: Key tail risks are a negative CMS/NCD decision or major payer denial within 90–180 days, and operational integration failures at scale (EHR interoperability, lab logistics). Immediate catalysts: JP Morgan conference this week and Renalytix February trading update; short-term (3–6 months) adoption hinge on 5–20 additional provider integrations and any Tempus rollouts into large diabetes populations; long-term (12–36 months) depends on demonstrable cost-savings that shift payer behavior. Hidden dependency: utilization ≠ integration — physician ordering behavior and coding/reimbursement capture are critical second-order constraints.

Trade implications: Small, staged long exposure to RNLXY (illiquid OTC) is warranted ahead of the February update, paired with a 6–9 month call-spread on TEM to lever the partnership channel while limiting premium paid. Consider a conditional relative-value short of DVA/FMS sized <1% if Renalytix reports >3 major health-system integrations or Tempus announces population-level deployment in 90 days — that’s the inflection for structural demand. Options: buy TEM 9‑month ATM call / sell 20% OTM call to fund; avoid naked longs in RENX due to liquidity and reimbursement risk.

Contrarian angles: The market both underestimates integration friction (risking overvaluation if you buy now) and underestimates optionality from Tempus-enabled rapid scaling (if one or two large payers or IDNs adopt, growth could be nonlinear). Historical parallel: early liquid biopsy plays took 2–4 years to convert clinical integrations into payer-funded volume — expect similar multi-year conversion, not instant revenue. Unintended consequences include payer pushback or provider substitution effects that could compress realized ASPs and force Renalytix to accept lower per-test pricing or revenue‑share models.

Key Decisions for Investors

• Initiate a 1.5% position in RNLXY (Renalytix OTC) within 5 business days ahead of the February update; set tactical stop-loss at -30% and plan to add +1.0% each time Renalytix confirms 3 additional payer-accepted integrations or cumulative live-provider count increases by ≥50% over current base within 90 days.
• Establish a 2% exposure to TEM via a 6–9 month call spread (buy ATM call, sell 20% OTM call) sized to risk no more than 1% of NAV; target 25–40% upside if Tempus announces population-level deployments within 90 days, close position if no material partnership expansion within 120 days.
• Enter a conditional pair trade: long 1.5% RNLXY vs short 0.75% DVA or FMS (pick the more liquid of DVA/FMS) if Renalytix reports ≥3 major health-system integrations or Tempus confirms deployments covering >100k diabetic patients within 120 days; cap pair exposure to 1.5% net to limit sector concentration.
• If CMS/Medicare issues an adverse coverage decision or a major payer publicly denies reimbursement for KidneyIntelX within 90 days, liquidate RNLXY position to zero and reduce TEM call-spread exposure by 50% within 5 trading days; conversely, if CMS signals favorable coverage within 180 days, increase RENX exposure to 3% and convert TEM spread to outright long calls.